生物标志物预测子痫前期不良结局的系统综述与荟萃分析
该系统综述检索1989年至2019年3月多个数据库,纳入33项研究共9426例疑似或确诊子痫前期孕妇,评估sFlt-1、PlGF及sFlt-1/PlGF比值预测不良结局的性能。PlGF和sFlt-1/PlGF比值对复合不良母婴结局、早产和胎儿生长受限的sROC曲线下面积在0.68至0.87之间,但研究间异质性大限制临床应用。
要点
- PlGF和sFlt-1/PlGF比值对子痫前期不良结局有预后价值。
- 复合不良母婴结局、早产和胎儿生长受限的sROC面积0.68-0.87。
- 研究间显著异质性(I2=33-99)限制标志物的临床实用性。
核心结论
- PlGF和sFlt-1/PlGF比值对子痫前期不良结局显示预后潜力,但研究异质性限制其临床效用。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、CINAHL、Cochrane、Scopus、ClinicalTrials.gov和Emcare数据库1989年至2019年3月。
- 初检3194篇文献,最终纳入33项研究,共9426例疑似或确诊子痫前期孕妇。
主要发现
- 纳入研究在评估的生物标志物和结局方面存在显著差异,荟萃分析部分仅纳入4至8项研究。
- 研究间异质性显著,I2范围为33至99。
- PlGF和sFlt-1/PlGF比值预测复合不良母婴结局、早产和胎儿生长受限的sROC曲线下面积在0.68至0.87之间。
临床怎么用
- PlGF和sFlt-1/PlGF比值可用于子痫前期不良结局的风险分层参考,但需考虑研究异质性对阈值和性能的影响。
局限性
- 纳入研究在生物标志物和结局评估方面显著变异,荟萃分析纳入研究数量少(4-8项)。
- 研究间异质性显著(I2=33-99),限制标志物临床应用的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review the performance of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and the sFlt-1/PlGF ratio in predicting adverse outcomes in women with preeclampsia. DATA SOURCES: We performed a systematic search of MEDLINE, EMBASE, CINAHL, Cochrane, Scopus, ClinicalTrials.gov, and Emcare databases from 1989 to March 2019 to identify studies correlating sFlt-1, PlGF, and the sFlt-1/PlGF ratio with the occurrence of adverse outcomes in women with preeclampsia. METHODS OF STUDY SELECTION: Two independent reviewers screened 3,194 studies using Covidence. Studies were included if they examined the performance of sFLT-1, PlGF, or the sFLT-1/PlGF ratio in predicting adverse outcomes in women with suspected or confirmed preeclampsia. TABULATION, INTEGRATION, AND RESULTS: We extracted contingency tables with true-positive, false-positive, true-negative, and false-negative results. We calculated sensitivity, specificity, diagnostic odds ratios, and area under the summary receiver operating characteristic curve (area sROC) through a bivariate mixed-effects meta-analysis. Our literature search identified 3,194 articles, of which 33 (n=9,426 patients) were included. There was significant variation in the included studies with regard to the biomarkers and outcomes assessed. As such, few studies (n=4-8) were included in the meta-analysis component with significant heterogeneity between studies (I2=33-99). Nonetheless, both PlGF and the sFlt-1/PlGF ratio demonstrated area sROC values between 0.68 and 0.87 for the prediction of composite adverse maternal and perinatal outcomes, preterm birth and fetal growth restriction. CONCLUSION: Placental growth factor and the sFlt-1/PlGF ratio show prognostic promise for adverse outcomes in preeclampsia, but study heterogeneity limits their clinical utility. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42019136207.
引用
- Lim S, Li W, Kemper J, et al. Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. Obstet Gynecol. 2021. PMID: 33278298. doi:10.1097/AOG.0000000000004149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。